Previous studies on Philadelphia chromosome positive (Ph+) CML and ALL have demonstrated that similar chromosome abnormalities (t(9;22)(q34;qll)) have resulted in (1) juxtaposition of c-abl to the middle portion of the bcr gene resulting in bcr-abl fused mRNA and protein in CML and ALL with a rearranged central region of bcr (Ph+, bcr+ cases) and (2) juxtaposition of c-abl to other unidentified sequences, resulting in novel c-abl mRNA and p190 protein product in Ph+, bcr- ALL cases (without rearrangement of the central region of bcr). To study the structure of the translocated c-abl gene in Ph+ bcr- ALL. we have isolated and sequenced cDNA clones covering the 5' end of the translocated c- abl fused mRNA from an established All cell line. Sequencing of the cDNA clone revealed that the c-abl second exon was fused to the 5' most exon of the bcr gene. This bcr 5' exon cDNA will be used to: isolate 5' __-genomic clones, to walk in the 3' direction of the bcr gene to the ALL breakpoint. and to define an All breakpoint cluster. Probes from the All break region (bcrALL) will be used to determine if changes in the All break region occur in Ph- acute leukemias and during transition from chronic to acute phase of CML. Poly A+ mRNA from All and CML cell lines will be used to develop a modified polymerase chain reaction method to amplify ALL type bcr-abl junctions from an mRNA template. The method will be used to detect residual disease aFter treatment in acute leukemia or emergence of All-type rearrangements, a possible indication of onset of acute phase, in chronic phase CML patients. Additionally, three new bcr-like loci have been described and mapped to chromosome 22 relative to the CML bcr gene. We will isolate and characterize genomic clones for these genes in order to localize and orient these genes relative to chromosome 22-linked genes and breakpoints.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047983-02
Application #
3817262
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22
Hol, F A; Hamel, B C; Geurds, M P et al. (1995) A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome. J Med Genet 32:52-6
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30

Showing the most recent 10 out of 75 publications